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VAP = ventilator-associated pneumonia.
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Nosocomial pneumonia is the most commonly acquired
infection in hospitalized patients, particularly those on
mechanical ventilators in the intensive care unit [1]. The
impact of this infection is dramatic, increasing mortality,
length of stay, and utilization of resources such as
mechanical ventilation and antibiotic therapy [2]. Nosocomial
pneumonia adds as much as $20,000 to hospital costs per
episode, and can increase hospital length of stay by as much
as 14 days [3]. In spite of aggressive, accurate therapy,
some patients die as a direct result of pneumonia, and it is
difficult to put a cost value on this endpoint. Patients who die
rapidly generally incur little excess cost of care, while those
who die after a prolonged hospital stay may require therapies
that lead to huge cost excesses. In terms of costs, as in other
areas, prevention of nosocomial pneumonia may be better
than effective treatment and cure.
Resistant organisms increase costs
Another factor has recently added to the cost impact of
nosocomial pneumonia, namely the increasing frequency of
infection caused by antibiotic-resistant organisms. The impact
of pneumonia can be even more dramatic if it involves a multi-
resistant Gram-positive organism (such as methicillin-resistant
Staphylococcus aureus) or a Gram-negative organism (such
as Pseudomonas aeruginosa or Acinetobacter spp.) [2].
Resistant organisms can add to costs in a number of ways.
First, since patients who acquire these organisms are already
very ill and the availability of effective therapy is limited,
pneumonia due to resistant organisms can lead to a higher
mortality and length of stay than pneumonia due to antibiotic-
sensitive organisms [2]. This may partly be the result of the
natural history of infection with such organisms, with some
organisms being more virulent than others, as well as a result
of the fact that patients infected with such organisms are
more likely to receive ‘inadequate’ initial empiric antibiotic
therapy [4].
In addition, infection with resistant organisms requires more
costly therapies. The effective antibiotics may be expensive and
may need to be given for a prolonged duration, often in
combination with multiple other agents. Management may cost
more because of the need for private isolation rooms, more
staff, and more equipment, such as gowns, gloves, masks, and
sterile medical equipment. Finally, the complications of infection
(such as delayed return to normal functional status, shock and
renal failure) and the need for tracheostomy may be greater in
patients infected with resistant organisms than in those infected
with sensitive organisms.
Cost of diagnosis
What can be done to control nosocomial pneumonia and add
to cost effective management? First, we must focus on
algorithms for diagnosis and therapy. For example,
controversy exists about whether to diagnose ventilator-
associated pneumonia (VAP) by invasive methods or by
clinical assessment. One argument in favor of invasive
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Abstract
Ventilator-associated pneumonia is a common illness in intensive care unit patients. The costs of
management are increased when infection involves resistant organisms, as well as unnecessary and
prolonged therapy. Efforts at accurate diagnosis, therapy and prevention can reduce the cost impact of
this illness.
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methods is that clinical diagnosis is too sensitive, and that
some patients receive antibiotic therapy unnecessarily, with
predictable impact on both costs and the emergence of
resistant organisms. One prospective, randomized controlled
trial in fact showed that patients managed with
bronchoscopic diagnosis had more antibiotic-free days than
patients managed clinically, without an adverse impact on
outcomes, and this certainly could add to cost effectiveness
[5]. While using fewer unnecessary antibiotics is a desirable
endpoint, it may also be achieved by careful and serial clinical
evaluation, using the Clinical Pulmonary Infection Score. In
one study, serial measurement of the Clinical Pulmonary
Infection Score, identifying patients who did not have
progressive clinical worsening, allowed investigators to
shorten duration of therapy in some patients, reducing
emergent antibiotic resistance [6]. These studies clearly
document the need for recognizing that some patients are
currently receiving therapy when it is not needed and are
being treated for too long.
Cost of therapy
The need to use antibiotics more selectively must, however,
be weighed against the observation that inadequate initial
empiric therapy of VAP is the most important determinant of
excess mortality [7]. One way to use antibiotics more
accurately is to have guidelines for usage that have been
adapted to local microbiologic patterns, recognizing that
each intensive care unit has its own unique patterns of
antibiotic resistance [8]. In addition, if these resistance
patterns are documented and used as a basis for antibiotic
selection, the accuracy and cost effectiveness of therapy can
be improved. A responsible and cost effective approach to
VAP may thus require the use of broad spectrum empiric
therapy, designed to avoid inadequate coverage of multi-
resistant pathogens, combined with a ‘de-escalation of
therapy’ in selected patients once culture data and clinical
evolution information become available.
Cost of prevention
Perhaps the most cost effective way to manage VAP is by
prevention and, while there are many proposed strategies, the
simplest will probably be the most effective. These strategies
include: positioning patients semi-erectly, not supine, using
endotracheal tubes that allow for subglottic secretion
drainage; maintaining endotracheal tube cuff pressures at
levels that prevent aspiration of pooled secretions above
them; monitoring for excess gastric residuals that can lead to
aspiration; feeding into the small bowel whenever possible to
avoid aspiration and bacterial translocation; careful handling
of ventilator circuits to avoid washing condensate back to
patients; and the use of non-invasive ventilation rather than
intubation whenever possible. In addition, several antibiotic
interventions may be effective, such as giving 24 hours of
therapy to patients with witnessed aspiration, rotation of
empiric regimens, and using selective digestive
decontamination in carefully selected populations [9].
In the future, our evaluation of new therapeutic approaches to
nosocomial pneumonia will clearly focus on a measurement
of improved outcomes, and not just on assessment of the
microbiologic and clinical response to antibiotic therapy.
While mortality is the ultimate endpoint to prove the value of
new approaches, cost effectiveness is also an important
goal. If achieved, cost effectiveness can point to great value
for new management strategies.
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